Nuvectis Pharma (NVCT) Equity Average (2021 - 2026)
Nuvectis Pharma has reported Equity Average over the past 6 years, most recently at $16.3 million for Q1 2026.
- Quarterly results put Equity Average at $16.3 million for Q1 2026, up 6.41% from a year ago — trailing twelve months through Mar 2026 was $16.3 million (up 6.41% YoY), and the annual figure for FY2025 was $14.1 million, up 28.35%.
- Equity Average reached $16.3 million in Q1 2026 per NVCT's latest filing, down from $21.2 million in the prior quarter.
- Across five years, Equity Average topped out at $21.2 million in Q4 2025 and bottomed at $1.8 million in Q1 2022.
- Median Equity Average over the past 5 years was $15.3 million (2025), compared with a mean of $14.8 million.
- The largest annual shift saw Equity Average surged 687.84% in 2022 before it plummeted 36.47% in 2024.
- Over 5 years, Equity Average stood at $17.3 million in 2022, then decreased by 16.49% to $14.4 million in 2023, then decreased by 28.33% to $10.4 million in 2024, then surged by 104.9% to $21.2 million in 2025, then decreased by 23.08% to $16.3 million in 2026.
- Business Quant data shows Equity Average for NVCT at $16.3 million in Q1 2026, $21.2 million in Q4 2025, and $20.4 million in Q3 2025.